Startup Impact Biomedicines Raises $22M to Bring Fedratinib to MF Patients

SAN DIEGO–(Business Wire)–Today, Impact Biomedicines (“Impact”) announced its launch to pioneer the development of life-changing treatments for patients with myeloproliferative neoplasms and other cancers. The Company’s pipeline is centered around fedratinib, a potent and highly selective oral small molecule JAK2 kinase inhibitor that is being developed initially for the treatment of myelofibrosis (MF) and polycythemia vera (PV). In conjunction with this launch, Impact is pleased to share that the U.S. Food and Drug Administration (FDA) has removed the clinical hold placed on fedratinib and that the company has received $22.5 million from Medicxi through a Series A financing.

Read more

Posted in Clinical Trials, Uncategorized and tagged , .

Leave a Reply

Your email address will not be published. Required fields are marked *